๐ฃ In June 2021, Novartis International AG announced receiving approval from the US Food & Drug Administration (FDA) for the Breakthrough Therapy Designation (BTD) to 177Lu-PSMA-617 in patients with conditions of metastatic castration-resistant prostate cancer (mCRPC).
โถ๏ธ ๐๐ข๐๐ฐ ๐
๐ฎ๐ฅ๐ฅ ๐๐๐ฉ๐จ๐ซ๐ญ ๐ฐ๐ข๐ญ๐ก ๐๐๐ญ๐๐ฌ๐ญ ๐๐ง๐ฌ๐ข๐ ๐ก๐ญ๐ฌ:- https://www.marknteladvisors.c....om/research-library/
#prostate_cancer_market #prostatecancer #cancer #biopharma #ultrasound #tumor #healthcare #marknteladvisors #marketresearch
